The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Matthew H. Kulke Talks About Telotristat Etiprate Benefitting Carcinoid Syndrome Patients

Published Online: 8:24 PM, Mon October 19, 2015


Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.



Kulke says telotristat etiprate could potentially represent a new class of treatment for patients with carcinoid syndrome, due to its ability to decrease serotonin levels. He adds that serotonin levels could present a problem for patients with carcinoid syndrome and lower levels may help avoid heart disease and fibrosis of the intestines.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.